Inhaled fexlamose for moderate to severe COPD
Part of Lungs & breathing clinical trials.
This study tests an inhaled medicine called fexlamose for people with moderate to severe COPD linked to smoking. It aims to see if taking fexlamose can help improve your breathing and reduce flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old
- Your COPD is caused by smoking and your lung function (FEV1) is between 25% and 60% of normal
- You use stable COPD medications and have not changed doses in the last 4 weeks
- You have had no more than 2 COPD flare-ups needing a hospital stay in the past year
- You do not have asthma, active infections, or certain other lung conditions (like bronchiectasis or cystic fibrosis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called XKH001 to see if it helps people with COPD (chronic lung disease) who have frequent flare-ups despite using regular inhaler medications. The goal is to reduce how often flare-ups happen and improve breathing.
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
This trial tests a new inhaled medication, HRS-9821, in healthy people and in people with COPD. For COPD patients, the goal is to see how safe and well-tolerated multiple doses are, which could lead to a new treatment option.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
This trial tests a new medicine, Hemay005, in adults with moderate to severe COPD who also have a chronic cough with mucus. It looks at how the drug affects certain markers in the body related to the disease.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.